A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA) 12 weeks after the last planned dose of study drug.

Official Title

An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Participants must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA greater than (\>) 1000 international units per milliliter (IU/mL)* Population A: HCV Pegylated interferon (Peg-IFN)/RBV treatment naive (received no prior HCV therapy)or Peg-IFN/RBV prior treatment with relapse* Population B: Peg-IFN/RBV prior null or partial responder* Participants must not have achieved undetectable HCV RNA 24 weeks after the last planned dose of study drug (SVR24) after at least 1 prior course of Peg IFN/RBV therapy of standard duration* Participant must have positive HIV antibody at Screening* Participant must have a diagnosis of HIV-1 infection \>6 months before Screening* Participants should be taking 1 of the following permissible highly active antiretroviral therapy (HAART) regimens for HIV continuously for 12 weeks prior to screening:
  2. * Atripla® or equivalent components (efavirenz, tenofovir, emtricitabine) * Efavirenz plus Epzicom® (abacavir, lamivudine) or equivalent components * Boosted atazanavir (atazanavir with ritonavir) plus Truvada® (tenofovir, emtricitabine) or equivalent components * Boosted atazanavir plus Epzicom®, or equivalent components * Raltegravir plus Truvada®, or equivalent components * Raltegravir plus Epzicom®, or equivalent components* Cluster of differentiation 4 (CD4) counts and human immunodeficiency virus Type 1 (HIV-1) ribonucleic acid (RNA) meeting acceptable criteria at Screening as specified in the protocol* Laboratory values within acceptable ranges at Screening as specified in the protocol
Exclusion Criteria:
  1. * Subjects anticipating a need to switch HAART regimens within 14 weeks after Day 1 or any switches occurring 12 weeks prior to Day 1* Use of azidothymidine (AZT), didanosine (ddI) or stavudine (d4T) nucleosides* Contraindications to any planned HAART component as per the respective drug labeling information* Contraindications to Peg-IFN or RBV* Evidence of hepatic decompensation* Clinical suspicion of acute hepatitis* Any other cause of liver disease in addition to hepatitis C* History of organ transplantation (except cornea and skin)* Autoimmune-mediated disease* Participated in any investigational drug study within 90 days before Day 1* Previous treatment with an HCV protease inhibitor


Philip Grant
Philip Grant
Positive care doctor, Infectious disease doctor
Clinical Associate Professor, Medicine - Infectious Diseases
Andrew Zolopa

Contact us to find out if this trial is right for you.


Debbie Slamowitz
(650) 723-2804